As shown in Table 4 and Fig 4, the results of univariate analysis showed low PAXIP1-AS1 expression levels were associated with worse PFS (HR: 1.776; 95% CI: 1.067–2.955; P = 0.001), primary therapy outcome (HR: 0.401; 95% CI: 0.304–0.528; P<0.001), and tumor residual (HR: 1.695; 95% CI: 1.219–2.358; P = 0.002). The gene discussed is PAXIP1; the disease is neoplasm.